Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking.



Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics.



Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1(st) (11.1 months) and 2(nd) line (10.5) and decreased in lines 3 through 5 (3(rd): 7.9; 4(th): 7.2, 5(th): 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months).



Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.
a Tisch Cancer Institute/Multiple Myeloma Program , Mt. Sinai Cancer Institute , New York , NY , USA.
Sundar
S
Jagannath
b Global Market Access & Policy , Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.
Anuja
A
Roy
c Formerly with Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA.
Jonathan
J
Kish
d Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA.
Orsolya
O
Lunacsek
b Global Market Access & Policy , Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.
Denise
D
Globe
d Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA.
Michael
M
Eaddy
b Global Market Access & Policy , Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA.
Emil T
ET
Kuriakose
d Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA.
Joanne
J
Willey
d Global Health Economics and Outcomes Research, Xcenda , Palm Harbor , FL , USA.
Stephanie
S
Butler-Bird
e John Theurer Cancer Center , Hackensack University Medical Center , Hackensack , NJ , USA.
David
D
Siegel
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000453:epidemiology / Q000401:mortality* / Q000628:therapy*; D009367:Neoplasm Staging; D011159:Population Surveillance; D010818:Practice Patterns, Physicians'; D012008:Recurrence; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
Multiple myeloma; duration of therapy; progression-free survival; real-world evidence; relapsed/refractory; treatment patterns